• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Gaps in Oversight of Conflicts of Interest in Medicare Prescription Drug Decisions.
【24h】

Gaps in Oversight of Conflicts of Interest in Medicare Prescription Drug Decisions.

机译：监督医疗保险处方药决定中的利益冲突。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Federal law and regulations require Medicare Part D Pharmacy and Therapeutics (P&T) committees to make prescription drug coverage decisions based on scientific evidence and standards of practice. Formulary decisions affect beneficiaries access to specific prescription drugs and the cost of drugs to beneficiaries and the Federal Government. To comply with the law, sponsors P&T committees must prevent conflicts of interest from influencing members to give preference to certain drugs. In addition, sponsors P&T committees must comply with Federal law and regulations that specifically address conflicts on P&T committees by requiring that at least one physician and at least one pharmacist on each committee be independent and free of conflict relative to the sponsor and pharmaceutical manufacturers. The objectives of this report were to: 1. To assess sponsors Pharmacy and Therapeutics (P&T) committees conflict-of interest-definitions. 2. To determine whether sponsors P&T committees established objective processes to determine and manage committee members conflicts of interest. 3. To determine whether the Centers for Medicare & Medicaid Services (CMS) oversee sponsors P&T committee compliance with conflict-of-interest requirements.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号